Pricing Log in Create free account

Apimeds Pharmaceuticals US, Inc. (APUS) vs InMed Pharmaceuticals Inc. (INM)

Apimeds Pharmaceuticals US, Inc. and InMed Pharmaceuticals Inc. are both Drug Manufacturers Specialty & Generic companies. InMed Pharmaceuticals Inc. is the larger, with a market value of $7.3M against $6.6M — 1.1× the size. Across the 10 metrics below, InMed Pharmaceuticals Inc. leads on 7 and Apimeds Pharmaceuticals US, Inc. on 3.

Valuation

Metric APUS INM Drug Manufacturers Specialty & Generic median
P/E n/m n/m 19.25
P/S n/m 0.95 2.11
P/B 0.07 5.11 1.78
Price to free cash flow n/m n/m 16.14
EV/EBITDA n/m n/m 12.58
EV/Sales n/m 0.58 2.73
Earnings yield (905.20%) (228.36%) (4.38%)
Free cash flow yield (192.65%) (158.00%) 0.00%

Profitability

Metric APUS INM Drug Manufacturers Specialty & Generic median
Gross margin — 26.27% 53.94%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (100.13%) (179.09%) (0.40%)
Return on assets (84.20%) (139.63%) (3.32%)
Return on invested capital (15.96%) 0.00% 0.00%

Growth

Metric APUS INM Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) — 19.38% 10.01%
EPS growth (last fiscal year) (205.56%) 62.68% 49.06%
Revenue growth, 5-year CAGR — — 6.74%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric APUS INM Drug Manufacturers Specialty & Generic median
Debt to equity 0.08 0.00 0.05
Current ratio 0.51 1.37 2.31
Net debt to EBITDA 0.38 0.20 0.97

Dividend

Metric APUS INM Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.57%
Payout ratio — — 0.27

Size

Metric APUS INM Drug Manufacturers Specialty & Generic median
Market cap 6.62m 7.31m 276.90m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack